Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
By C. Bennett, S. Silver, B. Djulbegovic, A. Samaras, C. Blau, Kara J. Gleason, S. Barnato, Kathleen M. Elverman, D. Courtney, J. McKoy and 11 more. Journal of the American Medical Association (JAMA), 2008
755 citations recorded by the source corpus.
Subfields: Hematology, Internal Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/a47171ae7cd9fe562e008f29b69ad6ac58e45d6b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- D-dimer antigen: current concepts and future prospects. (2009, methodology): “use of this growth factor in the treatment of anemia in patients on hemodialysis, with cancer/chemotherapy-related anemia, and in other disorders.(85,86) A markedly elevated hematocrit has been shown to activate coagulation, but the elevation of the hematocrit”
- Epidemiology of cancer-associated venous thrombosis. (2013, result): “%) compared with oxaliplatin (6.5%).34 A systematic review of randomized controlled trials demonstrated that cancer patients treated with ESAs in addition to red blood cell transfusions had an increased risk of thromboembolic events over patients not additionally treated with ESAs (RR 1.7).35 These ”